Short Interest in Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Decreases By 16.6%

Nautilus Biotechnology, Inc. (NASDAQ:NAUT) was the recipient of a large drop in short interest in the month of January. As of January 30th, there was short interest totaling 307,305 shares, a drop of 16.6% from the January 15th total of 368,545 shares. Based on an average trading volume of 196,885 shares, the short-interest ratio is currently 1.6 days. Approximately 0.4% of the shares of the stock are sold short. Approximately 0.4% of the shares of the stock are sold short. Based on an average trading volume of 196,885 shares, the short-interest ratio is currently 1.6 days.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Sentinel Trust Co. LBA acquired a new stake in Nautilus Biotechnology during the 4th quarter worth approximately $1,462,000. Corient Private Wealth LLC raised its stake in shares of Nautilus Biotechnology by 860.0% during the second quarter. Corient Private Wealth LLC now owns 435,350 shares of the company’s stock valued at $316,000 after acquiring an additional 390,000 shares during the last quarter. Jacobs Levy Equity Management Inc. acquired a new position in shares of Nautilus Biotechnology during the first quarter worth $194,000. Y Intercept Hong Kong Ltd acquired a new stake in shares of Nautilus Biotechnology in the second quarter valued at about $163,000. Finally, Jane Street Group LLC raised its holdings in Nautilus Biotechnology by 304.1% during the 2nd quarter. Jane Street Group LLC now owns 290,369 shares of the company’s stock worth $210,000 after purchasing an additional 218,512 shares during the last quarter. Institutional investors and hedge funds own 50.71% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on NAUT shares. Wall Street Zen raised Nautilus Biotechnology from a “sell” rating to a “hold” rating in a report on Tuesday, November 18th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Nautilus Biotechnology in a report on Thursday, January 22nd. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock presently has a consensus rating of “Sell” and a consensus target price of $2.50.

Nautilus Biotechnology Stock Up 2.8%

Shares of NASDAQ NAUT traded up $0.06 during midday trading on Monday, reaching $2.19. 142,145 shares of the company were exchanged, compared to its average volume of 155,756. The stock’s 50-day moving average price is $2.01 and its 200-day moving average price is $1.45. The stock has a market cap of $276.62 million, a P/E ratio of -4.38 and a beta of 1.49. Nautilus Biotechnology has a one year low of $0.62 and a one year high of $2.54.

About Nautilus Biotechnology

Nautilus Biotechnology is a life sciences company developing a next-generation proteomics platform that aims to provide high-resolution, single-molecule protein analysis. Its core technology combines proprietary microfluidics, advanced optics and custom reagents to capture and identify thousands of proteins simultaneously, offering researchers detailed insights into cellular processes and disease biology. The company’s platform is designed to improve sensitivity, reproducibility and throughput compared with traditional mass spectrometry approaches.

Founded in 2016 and headquartered in Seattle, Washington, Nautilus Biotechnology serves pharmaceutical and biotechnology companies, academic institutions and research organizations seeking to accelerate drug discovery and biomarker research.